COURT-RULING ·Filed Jul 16, 2026

CGON

CG Oncology, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed2mo ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight • Neutral

Monitor for the full opinion text or a subsequent press release from either party. A ruling against CG Oncology could threaten its pipeline or market exclusivity, while a win removes a key overhang. Given the low confidence, no immediate trade is warranted.

DirectionNeutral
Confidencelow
Horizondays
Latest settled — T+20d ⚠ clustered
CGON ▲ +7.50% at T+20d
NEUTRAL call ✓ call won +7.50% · α vs SPY +3.88% · entry $69.50 → $74.71
Next anchor: T+60d in 6d
Latest observation: T+52 +10.75% FF3 residual α
Entry anchored
Jul 15, 03:59 PM ET
via exchange tick
T+1d
+3.38%
call +3.38% · α +4.37%
$71.85
settled 3mo ago
T+5d
+2.33%
call +2.33% · α +4.00%
$71.12
settled 2mo ago
T+20d
+7.50%
call +7.50% · α +3.88%
$74.71
settled 7w ago
T+60d
—
call — · α —
—
in 6d

Price Chart

Loading chart...

Executive Summary

CG Oncology is the defendant in a Delaware Superior Court patent infringement case filed by ANI Pharmaceuticals. The opinion body was unavailable, so the ruling's direction and reasoning are unknown. This introduces uncertainty but the case itself represents a potential risk to CG Oncology's intellectual property position.

Court Ruling Details

Ruling Date
Jul 16, 2026
Court
Delaware Superior Court
Court Level
District
Case Type
patent
Ruling Type
other
Will It Be Appealed?
N/A (final)
Precedent Risk
MEDIUM

Key Facts

  • CG Oncology is the defendant in a patent infringement lawsuit filed by ANI Pharmaceuticals.
  • The case is pending in the Delaware Superior Court (CCLD), docket N24C-03-022 SKR CCLD.
  • The full opinion text was unavailable, preventing determination of the ruling's outcome or reasoning.

Financial Impact

Not determinable — opinion text unavailable; potential IP risk to CG Oncology's product portfolio.

revenueip_value

Risk Factors

  • Adverse patent ruling could block or delay CG Oncology's product commercialization.
  • Ongoing litigation creates legal expense and management distraction.
  • Opinion text unavailability means the market may react sharply once details emerge.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-a3d1f282d5-CGON
17 reports for CGON
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+20▲ +26.33%Jun 12, 2026
Filters
Rows
Reports for CGON — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
Press Release
BEARISH ★ 7/10
$74.85 $74.33▲ +0.69%▲ +1.29%$67.38 (+9.98%)
Aug 6, 2026
8w ago
424B5
BEARISH ★ 6/10
$74.85 $74.33▲ +0.69%▲ +1.29%$67.38 (+9.98%)
Jul 27, 2026
9w ago
Press Release
BULLISH ★ 7/10
$72.62 $78.95▲ +8.72%▲ +5.34%$67.38 (−7.22%)
Jul 17, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.85 $75.03▲ +4.43%▼ −0.02%$67.38 (−6.22%)
Jul 16, 2026
11w ago
Court Ruling
NEUTRAL ★ 4/10
$69.50 $74.71▲ +7.50%▲ +3.88%$67.38 (−3.05%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$72.84 $71.12▼ −2.36%▼ −2.89%$67.38 (−7.50%)
Jun 22, 2026
14w ago
144
NEUTRAL ★ 3/10
$65.73 $70.19▲ +6.79%▲ +5.63%$67.38 (+2.51%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$59.56 $75.24▲ +26.33%▲ +24.55%$67.38 (+13.13%)
May 26, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$61.89 $70.25▲ +13.50%▲ +15.45%$67.38 (+8.87%)
May 15, 2026
20w ago
Press Release
BULLISH ★ 6/10
$66.93 $59.56▼ −11.01%▼ −13.13%$67.38 (+0.67%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (39h 28m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access